CB1 receptor modulator showed antipsychotic potential without THC-like side effects in rats
The CB1 receptor positive allosteric modulator GAT211 reduced hyperlocomotion caused by NMDA receptor blockade in rats and limited dopamine D2 receptor signaling in cells, suggesting antipsychotic potential distinct from THC.
Quick Facts
What This Study Found
GAT211 dose-dependently reduced locomotor activity, prevented MK-801-induced hyperlocomotion (a model of psychosis), and limited dopamine D2 receptor-mediated ERK phosphorylation in neuronal cells. Unlike THC, GAT211 blocked the dopaminergic signaling pathway associated with psychotic behavior.
Key Numbers
GAT211 doses: 0.3-3.0 mg/kg; MK-801 dose: 0.15 mg/kg; GAT211 3.0 mg/kg prevented MK-801 hyperlocomotion; GAT211 limited D2-mediated ERK phosphorylation; THC did not
How They Did This
Researchers compared GAT211 and THC effects on dopamine D2 receptor signaling in Neuro2a cells and on behavior in male Long Evans rats treated with MK-801 (NMDA antagonist) to model psychosis. Locomotor activity and prepulse inhibition of acoustic startle were measured.
Why This Research Matters
Current antipsychotics have significant side effects. CB1 receptor positive allosteric modulators represent a fundamentally different pharmacological approach that could modulate the endocannabinoid system without the psychoactive effects of direct CB1 agonists like THC.
The Bigger Picture
This study opens a new therapeutic direction. Rather than blocking dopamine receptors (like current antipsychotics) or activating CB1 directly (like THC), positive allosteric modulators fine-tune CB1 activity to modulate dopamine signaling without psychoactive effects.
What This Study Doesn't Tell Us
Animal study with a single species and sex (male rats). GAT211 did not significantly improve prepulse inhibition deficits. Mechanism of action not fully elucidated. No human data.
Questions This Raises
- ?Would GAT211 work in other animal models of psychosis?
- ?Could it address negative symptoms of schizophrenia that current antipsychotics miss?
- ?What is the safety profile at therapeutic doses?
- ?How would it compare to CBD, which also has proposed antipsychotic effects?
Trust & Context
- Key Stat:
- GAT211 blocked D2-mediated ERK signaling; THC did not
- Evidence Grade:
- Preclinical study with both in vitro and in vivo components, but no human data and limited to male rats.
- Study Age:
- Published in 2021.
- Original Title:
- Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies.
- Published In:
- Psychopharmacology, 238(4), 1087-1098 (2021)
- Authors:
- McElroy, Dan L(7), Roebuck, Andrew J(4), Scott, Gavin A, Greba, Quentin, Garai, Sumanta, Denovan-Wright, Eileen M, Thakur, Ganesh A, Laprairie, Robert B, Howland, John G
- Database ID:
- RTHC-03335
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How is this different from THC?
GAT211 is a positive allosteric modulator that fine-tunes CB1 receptor activity rather than directly activating it like THC. In this study, GAT211 blocked dopamine D2 signaling associated with psychosis, while THC did not.
Could this become a new antipsychotic?
It shows preclinical promise, but has only been tested in cells and rats. Human clinical trials would be needed to determine safety and effectiveness, which is likely years away.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03335APA
McElroy, Dan L; Roebuck, Andrew J; Scott, Gavin A; Greba, Quentin; Garai, Sumanta; Denovan-Wright, Eileen M; Thakur, Ganesh A; Laprairie, Robert B; Howland, John G. (2021). Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies.. Psychopharmacology, 238(4), 1087-1098. https://doi.org/10.1007/s00213-020-05755-x
MLA
McElroy, Dan L, et al. "Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies.." Psychopharmacology, 2021. https://doi.org/10.1007/s00213-020-05755-x
RethinkTHC
RethinkTHC Research Database. "Antipsychotic potential of the type 1 cannabinoid receptor p..." RTHC-03335. Retrieved from https://rethinkthc.com/research/mcelroy-2021-antipsychotic-potential-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.